Pneumococcal Vaccines Market Overview

The report is titled ‘Pneumococcal Vaccines Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the pneumococcal vaccines market is the main objective of the report, which further consists of the market opportunity and insights of the data involved in the making of the respective market. The pneumococcal vaccine market is expected to grow at a significant rate in the near future.

The global pneumococcal vaccines market in 2020 is estimated for more than US$ 8,222.9 Mn and expected to reach a value of US$ 12,241.9 Mn by 2028 with a significant CAGR of 5.1%.

Pneumococcal Vaccines Market Dynamics

Increasing awareness about the importance of vaccination, growing government initiatives for the promotion and maintenance of better healthcare infrastructure, on-going, and continuous research & development activities in the healthcare sector, and the elevating adoption of vaccines are the major growth driving factors elevating the growth of global pneumococcal vaccines market.

Implementation of the regular immunization program, growing investments by the private sector in the healthcare industry, mounting cases of patients suffering from pneumococcal contaminations, and the elevating production of novel vaccinations also influence the positive growth of the market.

Increasing the count of the patient pool, developing the pharmaceutical industry, and improving health care infrastructure globally are some other reasons supporting the market growth.

However, the requirement of a longer period for the production of vaccines and the high cost associated with the production procedure tends to hamper the market growth. Furthermore, many key manufacturers find it costly compared to its returns, these limits and affect the overall business thereby retarding the overall market growth.

These vaccines also have some limitations and side effects, the vaccine aids the prevention of disease caused by streptococcus pneumonia bacterium, but, at the same time, it is ineffective in case of pneumonia caused by other bacteria.

On the contrary, the innovation of protein-based vaccines for treating and curing pneumonia is anticipated to create opportunities for the expansion of this market during the forecast period. Whereas, the public-private partnership serves to be the major market trending factor for the global pneumococcal vaccines market.

Pneumococcal Vaccines Market Segmentation

The global pneumococcal vaccines market is segmented on the basis of product type, distribution channel, sector, and region.

By Product Type:

    Synflorix

    Prevenar-13

    PCV 13 (pipeline)

    V114 (Merck)

    PCV-20 (Pfizer)

    PCV-10 (SII)

    PPSV- 23

By Distribution Channel:

    Wholesalers

    Specialized Companies

    Public Authorities

    Others

By Sector:

    Public

    Private 

By Region:

    North America

    Europe

    Asia Pacific

    Latin America

    Middle East

    Africa

Pneumococcal Vaccines Market Pipeline Drugs Overview

In the global pneumococcal vaccines market, several numbers of drugs are in a pipeline including, V114. V114 is an investigational vaccine currently being evaluated for its ability to provide protection against pneumococcal disease caused by serotypes contained in the vaccine.

GlaxoSmithKline also has a 10-serotype drug in phase 2 trials that are formulated in such a way that it could provide more coverage than Prevnar 13.  Rising government and non-governmental initiatives including GAVI, WHO, and UNICEF to offer vaccination to developing nations like China and India. For instance, GAVI has contributed to Advanced Market Commitment to provide pneumococcal vaccines to 60 countries as a regular immunization program.

The pneumococcal Advance Market Commitment (AMC) is designed to protect children against pneumococcal disease.  It is estimated that the pilot can prevent more than 1.5 million childhood deaths by 2020.

Pneumococcal Vaccines Market Competitive Landscape

Key players operating in the global pneumococcal vaccines market include Chengdu Institute of Biological Products Co., Ltd., CSL Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Pfizer, Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., SK Chemicals, and Walvax Biotechnology Co., Ltd.

Regional Segmentation

On the basis of region, the pneumococcal vaccines market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.

MMC Overview on Pneumococcal Vaccines Market Report

The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give better opportunity for the customers to put their effort.

A research report on the Pneumococcal Vaccines market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that supports market and the factors that are acting as impedance for the growth of the market.

Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth include (but not restricted to):

•    New product designs and launches

•    Current product compliance

•    Reimbursement

•    Concerns for use of Pneumococcal Vaccines

•    Advantages of Pneumococcal Vaccines

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to make an informed decision.

A mix of top-down and bottom-up approach is followed to arrive at and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s products sales, previous growth rates and market expansion plans are considered to generate market share in the global market.

1.    Global Pneumococcal Vaccines Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global Pneumococcal Vaccines Market Overview

2.1.    Introduction

2.1.1.    Market Definition

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global Pneumococcal Vaccines Market Snapshot

2.4.    Global Pneumococcal Vaccines Market Size and Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    Global Pneumococcal Vaccines Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Key Regulations

2.7.    Porter’s Five Forces Model

3.    Global Pneumococcal Vaccines Market, By Product Type

3.1.    Introduction

3.1.1.    Annual Growth Rate Comparison, By Product Type

3.1.2.    BPS Analysis, By Product Type

3.2.    Market Revenue (US$Mn) Forecast, By Product Type

3.2.1.    Synflorix

3.2.2.    Prevenar-13

3.2.3.    PCV 13 (pipeline)

3.2.4.    V114 (Merck)

3.2.5.    PCV-20 (Pfizer)

3.2.6.    PCV-10 (SII)

3.2.7.    PPSV- 23

3.3.    Global Pneumococcal Vaccines Market Attractiveness Index, By Product Type

4.    Global Pneumococcal Vaccines Market, By Distribution Channel

4.1.    Introduction

4.1.1.    Annual Growth Rate Comparison, By Distribution Channel

4.1.2.    BPS Analysis, By Distribution Channel

4.2.    Market Revenue (US$Mn) Forecast, By Distribution Channel

4.2.1.    Wholesalers

4.2.2.    Specialized Companies

4.2.3.    Public Authorities

4.2.4.    Others

4.3.    Global Pneumococcal Vaccines Market Attractiveness Index, By Distribution Channel

5.    Global Pneumococcal Vaccines Market, By Sector

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Sector

5.1.2.    BPS Analysis, By Sector

5.2.    Market Revenue (US$Mn) Forecast, By Sector

5.2.1.    Public

5.2.2.    Private

5.3.    Global Pneumococcal Vaccines Market Attractiveness Index, By Sector

6.    Global Pneumococcal Vaccines Market, By Region

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Region

6.1.2.    BPS Analysis, By Region

6.2.    Market Revenue (US$Mn) Forecast, By Region

6.2.1.    North America

6.2.2.    Latin America

6.2.3.    Europe

6.2.4.    Asia Pacific

6.2.5.    Middle East

6.2.6.    Africa

6.3.    Global Pneumococcal Vaccines Market Attractiveness Index, By Region

7.    North America Pneumococcal Vaccines Market Analysis and Forecast, 2020–2028

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Country

7.1.2.    BPS Analysis, By Country

7.2.    Market Revenue (US$Mn) Forecast, By Country

7.2.1.    U.S. Pneumococcal Vaccines Market

7.2.2.    Canada Pneumococcal Vaccines Market

7.3.    North America Pneumococcal Vaccines Market, By Product Type

7.3.1.    Synflorix

7.3.2.    Prevenar-13

7.3.3.    PCV 13 (pipeline)

7.3.4.    V114 (Merck)

7.3.5.    PCV-20 (Pfizer)

7.3.6.    PCV-10 (SII)

7.3.7.    PPSV- 23

7.4.    North America Pneumococcal Vaccines Market, By Distribution Channel

7.4.1.    Wholesalers

7.4.2.    Specialized Companies

7.4.3.    Public Authorities

7.4.4.    Others

7.5.    North America Pneumococcal Vaccines Market, By Sector

7.5.1.    Public

7.5.2.    Private

7.6.    North America Pneumococcal Vaccines Market Attractiveness Index

7.6.1.    By Country

7.6.2.    By Sector

7.6.3.    By Distribution Channel

7.6.4.    By Product Type

8.    Latin America Pneumococcal Vaccines Market Analysis and Forecast, 2020–2028

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Country

8.1.2.    BPS Analysis, By Country

8.2.    Market (US$Mn) Forecast, By Country

8.2.1.    Brazil Pneumococcal Vaccines Market

8.2.2.    Mexico Pneumococcal Vaccines Market

8.2.3.    Argentina Pneumococcal Vaccines Market

8.2.4.    Rest of Latin America Pneumococcal Vaccines Market

8.3.    Latin America Pneumococcal Vaccines Market, By Product Type

8.3.1.    Synflorix

8.3.2.    Prevenar-13

8.3.3.    PCV 13 (pipeline)

8.3.4.    V114 (Merck)

8.3.5.    PCV-20 (Pfizer)

8.3.6.    PCV-10 (SII)

8.3.7.    PPSV- 23

8.4.    Latin America Pneumococcal Vaccines Market, By Distribution Channel

8.4.1.    Wholesalers

8.4.2.    Specialized Companies

8.4.3.    Public Authorities

8.4.4.    Others

8.5.    Latin America Pneumococcal Vaccines Market, By Sector

8.5.1.    Public

8.5.2.    Private

8.6.    Latin America Pneumococcal Vaccines Market Attractiveness Index

8.6.1.    By Country

8.6.2.    By Sector

8.6.3.    By Distribution Channel

8.6.4.    By Product Type

9.    Europe Pneumococcal Vaccines Market Analysis and Forecast, 2020–2028

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market (US$Mn) Forecast, By Country

9.2.1.    U.K. Pneumococcal Vaccines Market

9.2.2.    Germany Pneumococcal Vaccines Market

9.2.3.    Italy Pneumococcal Vaccines Market

9.2.4.    France Pneumococcal Vaccines Market

9.2.5.    Spain Pneumococcal Vaccines Market

9.2.6.    Russia Pneumococcal Vaccines Market

9.2.7.    Poland Pneumococcal Vaccines Market

9.2.8.    BENELUX Pneumococcal Vaccines Market

9.2.9.    NORDIC Pneumococcal Vaccines Market

9.2.10.    Rest of Europe Pneumococcal Vaccines Market

9.3.    Europe Pneumococcal Vaccines Market, By Product Type

9.3.1.    Synflorix

9.3.2.    Prevenar-13

9.3.3.    PCV 13 (pipeline)

9.3.4.    V114 (Merck)

9.3.5.    PCV-20 (Pfizer)

9.3.6.    PCV-10 (SII)

9.3.7.    PPSV- 23

9.4.    Europe Pneumococcal Vaccines Market, By Distribution Channel

9.4.1.    Wholesalers

9.4.2.    Specialized Companies

9.4.3.    Public Authorities

9.4.4.    Others

9.5.    Europe Pneumococcal Vaccines Market, By Sector

9.5.1.    Public

9.5.2.    Private

9.6.    Europe Pneumococcal Vaccines Market Attractiveness Index

9.6.1.    By Country

9.6.2.    By Sector

9.6.3.    By Distribution Channel

9.6.4.    By Product Type

10.    Asia Pacific Pneumococcal Vaccines Market Analysis and Forecast, 2020–2028

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    China Pneumococcal Vaccines Market

10.2.2.    India Pneumococcal Vaccines Market

10.2.3.    Japan Pneumococcal Vaccines Market

10.2.4.    Australia and New Zealand Pneumococcal Vaccines Market

10.2.5.    South Korea Pneumococcal Vaccines Market

10.2.6.    ASEAN Pneumococcal Vaccines Market

10.2.7.    Rest of Asia Pacific Pneumococcal Vaccines Market

10.3.    Asia Pacific Pneumococcal Vaccines Market, By Product Type

10.3.1.    Synflorix

10.3.2.    Prevenar-13

10.3.3.    PCV 13 (pipeline)

10.3.4.    V114 (Merck)

10.3.5.    PCV-20 (Pfizer)

10.3.6.    PCV-10 (SII)

10.3.7.    PPSV- 23

10.4.    Asia Pacific Pneumococcal Vaccines Market, By Distribution Channel

10.4.1.    Wholesalers

10.4.2.    Specialized Companies

10.4.3.    Public Authorities

10.4.4.    Others

10.5.    Asia Pacific Pneumococcal Vaccines Market, By Sector

10.5.1.    Public

10.5.2.    Private

10.6.    Asia Pacific Pneumococcal Vaccines Market Attractiveness Index

10.6.1.    By Country

10.6.2.    By Sector

10.6.3.    By Distribution Channel

10.6.4.    By Product Type

11.    Middle East Pneumococcal Vaccines Market, By Region

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Country

11.1.2.    BPS Analysis, By Country

11.2.    Market (US$Mn) Forecast, By Country

11.2.1.    GCC Countries Pneumococcal Vaccines Market

11.2.2.    Israel Pneumococcal Vaccines Market

11.2.3.    Oman Pneumococcal Vaccines Market

11.2.4.    Rest Of Middle East Pneumococcal Vaccines Market

11.3.    Middle East Pneumococcal Vaccines Market, By Product Type

11.3.1.    Synflorix

11.3.2.    Prevenar-13

11.3.3.    PCV 13 (pipeline)

11.3.4.    V114 (Merck)

11.3.5.    PCV-20 (Pfizer)

11.3.6.    PCV-10 (SII)

11.3.7.    PPSV- 23

11.4.    Middle East Pneumococcal Vaccines Market, By Distribution Channel

11.4.1.    Wholesalers

11.4.2.    Specialized Companies

11.4.3.    Public Authorities

11.4.4.    Others

11.5.    Middle East Pneumococcal Vaccines Market, By Sector

11.5.1.    Public

11.5.2.    Private

11.6.    Middle East Pneumococcal Vaccines Market Attractiveness Index

11.6.1.    By Country

11.6.2.    By Sector

11.6.3.    By Distribution Channel

11.6.4.    By Product Type

12.    Africa Pneumococcal Vaccines Market, By Region

12.1.    Introduction

12.1.1.    Annual Growth Rate Comparison, By Country

12.1.2.    BPS Analysis, By Country

12.2.    Market (US$Mn) Forecast, By Country

12.2.1.    South Africa Pneumococcal Vaccines Market

12.2.2.    Egypt Pneumococcal Vaccines Market

12.2.3.    North Africa Pneumococcal Vaccines Market

12.2.4.    Rest Of Africa Pneumococcal Vaccines Market

12.3.    Africa Pneumococcal Vaccines Market, By Product Type

12.3.1.    Synflorix

12.3.2.    Prevenar-13

12.3.3.    PCV 13 (pipeline)

12.3.4.    V114 (Merck)

12.3.5.    PCV-20 (Pfizer)

12.3.6.    PCV-10 (SII)

12.3.7.    PPSV- 23

12.4.    Africa Pneumococcal Vaccines Market, By Distribution Channel

12.4.1.    Wholesalers

12.4.2.    Specialized Companies

12.4.3.    Public Authorities

12.4.4.    Others

12.5.    Africa Pneumococcal Vaccines Market, By Sector

12.5.1.    Public

12.5.2.    Private

12.6.    Africa Pneumococcal Vaccines Market Attractiveness Index

12.6.1.    By Country

12.6.2.    By Sector

12.6.3.    By Distribution Channel

12.6.4.    By Product Type

13.    Recommendation

13.1.    Market Strategy

14.    Competitive Landscape

14.1.    Competition Dashboard

14.2.    List and Company Overview of Global Key Players

14.3.    Company Profiles

14.3.1.    Chengdu Institute of Biological Products Co., Ltd.

14.3.1.1.    Company Overview

14.3.1.2.    Financial Overview

14.3.1.3.    Product Portfolio

14.3.1.4.    Key Developments

14.3.1.5.    Business Strategies

14.3.2.    CSL Ltd.

14.3.3.    GlaxoSmithKline plc

14.3.4.    Merck & Co., Inc.

14.3.5.    Pfizer, Inc.

14.3.6.    Sanofi SA

14.3.7.    Serum Institute of India Pvt. Ltd.

14.3.8.    Serum Institute of India Pvt. Ltd.

14.3.9.    SK Chemicals

14.3.10.    Walvax Biotechnology Co., Ltd.

15.    Acronyms